Botulinum toxin treatment of adult spasticity

References

• Mayer NH, Simpson DM. Preface. In: Spasticity: Etiology Evaluation, Management and the Role of Botulinum Toxin. Mayer NH, Simpson DM (Eds). WeMove Organization, NY, USA (2002).
   Google Scholar
• Sheean G. Neurophysiology of spasticity. In: Clinical Management of Spasticity and the Upper Motor. Iiumne Synchame. Barnes MP, Johnson G (Eds). Cambridge University Press, Cambridge, UK, 12–78 (2001).
   Google Scholar
• Lance JW. Symposium synopsis. In: Spasticity: Disorclemd Motor Control. Feldman RG, Young RR, Koella WP (Eds). Year Book Medical Publishers, Chicago, IL, USA, 485–494 (1980).
   Google Scholar
• O'Dwyer NJ, Ada L, Neilson PD. Spasticity and muscle contracture following stroke. Brain. 119(5), 1737–1749 (1996).
   Google Scholar
• ••Casts doubt upon the long-acceptedrelationship between spasticity and the development of contractures. Spasticity was defined electrophysiologically as velocity-dependent stretch hyper-reflexia, not as clinical hypertonia. The dissociation between tone and stretch reflexes indicates the importance of soft tissue changes in the upper motor neuron syndrome.
   Google Scholar
• Denny-Brown D. The Cerebral Control of Movement. Liverpool University Press, Liverpool, UK (1966).
   Google Scholar
• Dietz V, Quintern J, Berger W. Electrophysiological studies of gait in spasticity and rigidity. Bain 104,431–449 (1981).
   Google Scholar
• Sinkjaer T, Toft E, Larsen K, Andreassen S, Hansen HJ. Nonreflex and reflex mediated ankle joint stiffness in multiple sclerosis patients with spasticity. Muscle Nerve 16, 69–76 (1993).
   Google Scholar
• Given JD, Dewald JP, Rymer WZ. Joint dependent passive stiffness in paretic and contralateral limbs of spastic patients with hemiparetic stroke. J. Neural Neurosurg. Psychiatry 59 (3), 271–279 (1995).
   Google Scholar
• Johnson GR. Measurement of spasticity. In: Clinical Management of Spasticity and the Upper Motor Neumne Syndrome. Barnes MP, Johnson G (Eds). Cambridge University Press, Cambridge, UK, 79–95 (2001).
   Google Scholar
• Boyd RN, Ada L. Physiotherapy management of spasticity. In: Clinical Management of Spasticity and the Upper Motor Neurone Syndrome. Barnes MP, Johnson G (Eds). Cambridge University Press, Cambridge, UK, 96–121 (2001).
   Google Scholar
• Dietz V. Spastic movement disorder: what is the impact of research on clinical practice?' Neurd Neurosurg. Bychiatry 74,820–821 (2003).
   Google Scholar
• Ada L, Vattanasilp W O'Dwyer NJ, Crosbie J. Does spasticity contribute to walking dysfunction after stroke?' .1%,uni. .1urasu1g. Bychiatry64(5), 628–635 (1998).
   Google Scholar
• Dickstein R, Heffes Y, Abulaffio N. Electromyographic and positional changes in the elbows of spastic hemiparetic patients during walking. Bectmencephalogi: Clin. Neumphysiol 101(6), 491–496 (1996).
   Google Scholar
• Young RR. Spasticity: a review. Neurology 44 (Suppl. 9), S12—S20 (1994).
   Google Scholar
• ••Provides an excellent overview of thepathophysiology and pharmacology of spasticity, well worth reading to gain a working understanding quickly.
   Google Scholar
• el-Abd MA, Ibrahim IK, Dietz V. Impaired activation pattern in antagonistic elbow muscles of patients with spastic hemiparesis: contribution to movement disorder. Dectromyogi: Clin. Neumphysiol 33(4), 247–255 (1993).
   Google Scholar
• Edwards S. Physiotherapy management of established spasticity. In: Spasticity Rehabilitation. Sheean G (Ed.). Churchill Communications Europe Ltd., London, UK, 71–90 (1998).
   Google Scholar
• Butler C, Darrah J. Effects of neurodevelopmental treatment (NDT) for cerebral palsy: an AACPDM evidence report. Dev Med. Child. Neural 43(11), 778–790 (2001).
   Google Scholar
• Richardson DR. Evaluation of interventions in the management of spasticity: treatment goals and outcome measures. In: Spasticity Rehabilitation. Sheean G (Ed.). Churchill Communications Europe Ltd, London, UK, 57–71 (1998).
   Google Scholar
• Pierson SH. Outcome measures in spasticity management. In: Spasticity: Etiology Evaluation, Management and the Role of Botulinum Toxin. Mayer NH, Simpson DM (Eds). WeMove Organization, NY, USA, 27–43 (2002).
   Google Scholar
• Cutter NC, Scott DD, Johnson JC, Whiteneck G. Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. Arch. Phys. Med Rehabil 81(2), 164–169 (2000).
   Google Scholar
• Meythaler JM, Guin-Renfroe S, Hadley MN. Continuously infused itntrathecal baclofen for spastiddystonic hemiplegia: a preliminary report. Am j Phys. Med. Rehabil 78(3), 247–254 (1999).
   Google Scholar
• Jarrett L, Nandi P, Thompson AJ. Managing severe lower limb spasticity in multiple sclerosis: does it. phenol have a role?" Neural Neurosurg. Ptychiatry73 (6), 705–709 (2002).
   Google Scholar
• Nathan PW, Sears TA, Smith MC. Effects of phenol solutions on the nerve roots of the cat: an electrophysiological and histological study. I Neural Sri. 2 (1), 7–29 (1965).
   PubMedGoogle Scholar
• Zafonte RD, Munin MC. Phenol and alcohol blocks for the treatment of spasticity. Phys. Med. Rehabil Gun. N Am. 12(4), 817–832 (2001).
   Google Scholar
• Trigaux JP, Deceone B, Van Beers B. Focal necrosis of the ureter following CT-guided chemical sympathectomy. Camliovasc Intervent. Radio!. 15(3), 180–182 (1992).
   Google Scholar
• Clli M, Aoki R Botulinum toxin A (BTX-a) reduces inflammatory pain in the rat formalin model. Cephalalgia 20,414 (2000).
   Google Scholar
• de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc. Natl Acad. Sc]. USA 96(6), 3200–3205 (1999).
   Google Scholar
• Berweck S, Feldkamp A, Francke A, Nehles J, Schwerin A, Heinen E Sonography-guided injection of botulinum toxin A in children with cerebral palsy. Neuropecliatrics 33(4), 221–223 (2002).
   PubMed Web of Science ®Google Scholar
• Perotto A. Anatomical Guide For the Electromyographer: The Limbs and Punk. Third Edition. Charles C Thomas Publishers, IL, USA (1994).
   Google Scholar
• Snow BJ, Tsui JK, Bhatt MH, Varelas M, Hashimoto SA, Caine DB. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neuml 28,512–515 (1990).
   PubMed Web of Science ®Google Scholar
• Simpson DM, Alexander DN, O'Brien CF eta! Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology46,1306-1310 (1996). Seminal study that established the efficacy of botulinum toxin in reducing distal upper limb hypertonia after stroke. The lessons learned from this study help understanding of why functional measures were not improved.
   Google Scholar
• Burbaud P, Wiart L, Dubos JL eta! A randomised, double-blind, placebo-controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. .1. Nemo'. Neumsurg. PTchiatry61, 265–269 (1996).
   Google Scholar
• Bakheit AM, Thilmann AF, Ward AB eta! A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 31,2402–2406 (2000).
   PubMed Web of Science ®Google Scholar
• Richardson D, Sheean G, Werring D et al Evaluating the role of botulinum toxin in the management of focal hypertonia in adults. .1. Neural Neurosurg. Psychiatry69, 499–506 (2000).
   Google Scholar
• **First double-blind study to use individualized injections of botulinum toxin and outcome measures in the hopes of demonstrating functional improvement. Despite this, only one measure of lower limb function was significantly improved.
   Google Scholar
• Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double-blind placebo-controlled trial. J. Nara. Neurosurg Bychiatry69,217–221 (2000).
   PubMed Web of Science ®Google Scholar
• Hyman N, Barnes M, Bhakta B eta! Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double-blind, placebo-controlled, dose ranging study. Neural Neurosurg. Fiychiatry8, 707–712 (2000).
   Google Scholar
• Smith SJ, Ellis E, White S, Moore AR A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Gun. Rehabil 14,5–13 (2000).
   Web of Science ®Google Scholar
• Bakheit AM, Pittock S, Moore AP eta! A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Euc Neural 8(6), 559–565 (2001).
   PubMed Web of Science ®Google Scholar
• Brashear A, Gordon ME, Elovic E eta! Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Eng. J. Med. 347(6), 395–400 (2002).
   Google Scholar
• Pittock SJ, Moore AP, Hardiman 0 eta! A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport®) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc. Dis. 15(4), 289–300 (2003).
   Google Scholar
• Fehlings D, Rang M, Glazier J, Steele C. An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. I Pecliatc 137(3), 331–337 (2000).
   Google Scholar
• Yang TF, Fu CP, Kao NT, Chan RC, Chen SJ. Effect of botulinum toxin type A on cerebral palsy with upper limb spasticity. Ainj Phys. Med. Rehabil 82(4), 284–289 (2003).
   Google Scholar
• Koman LA, Mooney JF 3rd, Smith BP, Walker F, Leon JM. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group. J. Pediatr. Orthop. 20(1), 108–115 (2000).
   Google Scholar
• Ade-Hall RA, Moore AP. Botulinum toxin type A in the treatment of lower limb spasticity in cerebral palsy. Cochrane Database Syst. Rev. (2) CD001408 (2000).
   Google Scholar
• van Kuijk AA, Geurts AC, Bevaart BJ, van Limbeek J. Treatment of upper extremity spasticity in stroke patients by focal neuronal or neuromuscular blockade: a systematic review of the literature. j Rehabil. Med. 34 (2), 51–61 (2002). Comprehensive review of the clinical trials of botulinum toxin treatment of spasticity after stroke.
   Google Scholar
• Sheean G. Botulinum toxin treatment of spasticity: why is it so hard to show a functional benefit? CU17: Opin. New& 14, 771–776 (2002). Explores the possible reasons why botulinum toxin injections have not shown convincing functional improvement in the placebo-controlled studies of spasticity.
   Google Scholar
• Rousseaux M, Kozlowski 0, Froger J. Efficacy of botulinum toxin A in upper limb function of hemiplegic patients. Nemo'. 249(1), 76–84 (2002).
   Google Scholar
• Bhatia IQ, Munchau A, Thompson PD et al Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases. J. New& Neurosurg. Psychiatry67(1), 90–93 (1999).
   Google Scholar
• Sheean GL, Murray NM, Marsden CD. Pain and remote weakness in limbs injected with botulinum toxin A for writer's cramp. Lancet 346(8968), 154–156 (1995).
   PubMed Web of Science ®Google Scholar
• Scott AB, Suzuki D. Systemic toxicity of botulinum toxin by im. injection in the monkey. Mov. Disord 3(4), 333–335 (1988).
   Google Scholar
• Molenaers G, Desloovere K, De Cat J eta! Single event multilevel botulinum toxin type A treatment and surgery: similarities and differences. Eur J. Neural 8\(Suppl. 5), 88–97 (2001).
   Google Scholar
• Eleopra R, Tugnoli V, De Grandis D. The variability in the clinical effect induced by botulinum toxin type A: the role of muscle activity in humans. Mov. Dion". 12(1), 89–94 (1997).
   Google Scholar
• Hesse S, Reiter F, Konrad M, Jahnke MT Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial. Clin. Rehabil12 (5), 381–388 (1998).
   PubMed Web of Science ®Google Scholar
• Detrembleur C, Lejeune TM, Renders A, Van Den Bergh PY. Botulinum toxin and short-term electrical stimulation in the treatment of equinus in cerebral palsy. Mov. Disord. 17(1), 162–169 (2002).
   Google Scholar
• Wiegand H, Erdmann G, Wellhoner 1111. 125I-labelled botulinum A neurotoxin: pharmacokinetics in cats after im. injection. Naunyn. Schmiedebergs Arrh. Pharmacol 292(2), 161–165 (1976).
   Google Scholar
• Priori A, Berardelli A, Mercuri B, Manfredi M. Physiological effects produced by botulinum toxin treatment of upper limb dystonia. Changes in reciprocal inhibition between forearm muscles. Brain 118(3), 801–807 (1995).
   PubMed Web of Science ®Google Scholar
• Modugno N, Priori A, Berardelli A, Vacca L, Mercuri B, Manfredi M. Botulinum toxin restores presynaptic inhibition of group Ia afferents in patients with essential tremor. Muscle Nerve 21 (12), 1701–1705 (1998).
   PubMed Web of Science ®Google Scholar
• Ceballos-Baumann AO, Sheean G, Passingham RE, Marsden CD, Brooks DJ. Botulinum toxin does not reverse the cortical dysfunction associated with writer's cramp. A PET study. Brain 120,571–582 (1997).
   Google Scholar
• Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 113(3), 400–404 (1993).
   PubMed Web of Science ®Google Scholar
• Burke D. Spasticity as an adaptation to pyramidal tract injury. In: Advances In Neurology' Functional Recovery In Neurological Disease. (Volume 44. Waxman SG (Ed.). Raven Press, NY, USA, 401–423 (1988).
   Google Scholar
• Girlanda P, Quartarone A, Sinicropi S eta! Botulinum toxin in upper limb spasticity: study of reciprocal inhibition between forearm muscles. Neumreport 8(14), 3039–3044 (1997).
   PubMed Web of Science ®Google Scholar
• On AY, Kirazli Y, Kismali B, Aksit R Mechanisms of action of phenol block and botulinus toxin Type A in relieving spasticity: electrophysiologic investigation and follow-up. Am. J. Ph). Med. Rehabil 78(4), 344–349 (1999).
   Google Scholar
• Pandyan AD, Vuadens P, van Wijck FM, Stark S, Johnson GR, Barnes MP. Are we underestimating the clinical efficacy of botulinum toxin (type A)? Quantifying changes in spasticity, strength and upper limb function after injections of Botox to the elbow flexors in a unilateral stroke population. Clin. Rehabil 16(6), 654–660 (2002).
   PubMed Web of Science ®Google Scholar
• Schmit BD, Dewald JP, Rymer WZ. Stretch reflex adaptation in elbow flexors during repeated passive movements in unilateral brain-injured patients. Arch. Phys. Med. Rehabil 81(3), 269–278 (2000).
   Google Scholar
• Chalkiadaki A, Rohr UP, Hefter H. Early pain reduction in the treatment of spasticity after a single injection of botulinum A toxin. Dtsch Med. Wochenschr 126(48), 1361–1364 (2001).
   Google Scholar
• Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 40,445–450 (2000).
   Google Scholar
• Sheean G. The treatment of musculoskeletal pain and spasm with botulinum toxin. Cur Pain Headache Rep. 6,460–469 (2002).
   PubMedGoogle Scholar